UK markets close in 3 hours 29 minutes
  • FTSE 100

    7,480.25
    -2.12 (-0.03%)
     
  • FTSE 250

    19,983.19
    -135.25 (-0.67%)
     
  • AIM

    916.80
    -3.11 (-0.34%)
     
  • GBP/EUR

    1.1839
    -0.0007 (-0.05%)
     
  • GBP/USD

    1.2101
    +0.0020 (+0.16%)
     
  • BTC-GBP

    19,249.65
    -803.68 (-4.01%)
     
  • CMC Crypto 200

    540.42
    -2.45 (-0.45%)
     
  • S&P 500

    4,140.06
    -5.13 (-0.12%)
     
  • DOW

    32,832.54
    +29.04 (+0.09%)
     
  • CRUDE OIL

    91.90
    +1.14 (+1.26%)
     
  • GOLD FUTURES

    1,807.00
    +1.80 (+0.10%)
     
  • NIKKEI 225

    27,999.96
    -249.28 (-0.88%)
     
  • HANG SENG

    20,003.44
    -42.33 (-0.21%)
     
  • DAX

    13,528.75
    -158.94 (-1.16%)
     
  • CAC 40

    6,490.17
    -34.27 (-0.53%)
     

Autism Pipeline Drugs and Companies Guide 2021 - ResearchAndMarkets.com

·4-min read

DUBLIN, December 03, 2021--(BUSINESS WIRE)--The "Autism Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials" report has been added to ResearchAndMarkets.com's offering.

The global comprehensive report presents key-decision makers with critical insights into Autism pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

Autism pipeline Drug Snapshot, 2021

The Autism pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Autism. In addition to recent status, overview of drugs is included in the study. Wide range of Autism drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

Autism drug development pipeline by phase

The Autism pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Autism pipeline candidates is provided in the report enables you to understand timetable developments in Autism therapeutic area.

Autism pipeline drug Technology, Licensing and Collaboration Details

Details of technologies used for development of Autism pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Autism research study. Companies looking to partner with other players are also detailed in the report.

Autism- mechanism of action of pipeline candidates

Autism pipeline guide details the mechanism of action of each of the drug candidates under development. Further, leading types of mechanism of action (MoA) targeted by different Autism companies are identified to support decision makers target the most potential drugs under development.

Furthermore, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Autism drug administration.

Autism Drugs- Preclinical and Clinical Trials

This chapter in Autism preclinical and clinical trials assists in gaining clear understanding of the timetable developments in Autism product area. Preclinical and clinical trial details of pipeline candidates for Autism are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

Autism companies and Profiles

Companies developing Autism pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Autism Market Developments

The report presents the recent news and developments in the Autism pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Scope of the Report

  • Disease overview including Autism symptoms, widely used treatment options, companies and other details are included

  • Autism Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.

  • Autism pipeline drug count by phase, company and mechanism of action

  • Autism companies investing R&D resources in pipeline

  • Dominant Mechanism of Action

  • Most researched route of administration

  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included

  • Clinical trial information for each Autism pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details

  • Autism companies including their business snapshot, business description and Autism pipelines are included.

  • Recent Autism market developments, pipeline news and deals are provided

For more information about this report visit https://www.researchandmarkets.com/r/uf0rms

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005374/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting